导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.59% | 1577/4773 |
| 近一周 | -2.10% | 1235/5462 |
| 近一月 | -1.36% | 926/5421 |
| 近一季 | -1.53% | 1021/5209 |
| 近半年 | -6.83% | 3145/4920 |
| 近一年 | 8.64% | 1169/4366 |
| 近两年 | 44.17% | 1679/2954 |
| 近三年 | 37.21% | 793/2253 |
| 成立以来 | 116.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.26% 554/4961 |
-5.74% 3614/5312 |
- - |
- - |
| 2025 | 16.23% 2473/4813 |
-1.92% 2816/3635 |
-0.08% 2805/4076 |
13.79% 2965/4524 |
4.23% 555/4813 |
| 2024 | 16.70% 774/3463 |
7.83% 219/2808 |
0.55% 582/3014 |
8.66% 2731/3129 |
-0.95% 1550/3463 |
| 2023 | 8.79% 122/2656 |
6.67% 661/2280 |
1.76% 201/2385 |
1.91% 267/2515 |
-1.65% 353/2655 |
| 2022 | -10.11% 198/2207 |
-0.50% 130/1919 |
-1.61% 1746/2016 |
-9.19% 253/2113 |
1.11% 1383/2208 |
| 2021 | 24.40% 120/1822 |
8.44% 64/1255 |
2.64% 993/1330 |
7.09% 196/1466 |
4.36% 337/1822 |
| 2020 | 24.68% 630/1250 |
-5.41% 417/1028 |
10.99% 751/1067 |
15.73% 199/1164 |
2.63% 977/1184 |
| 2019 | - - |
- - |
- - |
-0.23% 586/850 |
5.19% 738/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证价值ETF联接C VS. 长安沪深300非周期A(740101) |